Press Releases BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
2.35 ^USD	-6.37%		-6.75%	-20.34%

Apr. 22	BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment	MT
Apr. 22	BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024	Apr. 25	AQ
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting	Apr. 24	AQ
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	Apr. 22	AQ
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia	Apr. 10	AQ
BioXcel Therapeutics Announces $25 Million Registered Direct Offering	Mar. 25	AQ
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine	Mar. 15	AQ
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023	Mar. 12	AQ
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024	Mar. 01	AQ
BioXcel Therapeutics Announces Termination of Proposed Public Offering	Feb. 13	AQ
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)	Feb. 12	AQ
BioXcel Therapeutics Announces Proposed Public Offering	Feb. 08	AQ
BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®	Feb. 06	AQ
BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine	Feb. 05	AQ
BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today	Dec. 12	AQ
BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs	Dec. 11	AQ
Moore Kuehn, PLLC Encourages BioXcel Therapeutics, Inc. Investors to Contact Law Firm	Dec. 01	PR
BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023	Nov. 30	AQ
BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results	Nov. 14	AQ
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype	Nov. 08	AQ
BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)	Nov. 06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Press Releases

Filters